专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

US20210003555A1 A Radiomics-Based Imaging Tool to Monitor Tumor-Lymphocyte Infiltration and Outcome in Cancer Patients Treated by Anti-PD-1/PD-L1 有权
公开(公告)号：US20210003555A1
公开(公告)日：2021-01-07
申请号：US16630031
申请日：2018-07-13
申请人： Institut Gustave-Roussy
发明人： Charles FERTE , Elaine Johanna LIMKIN , Roger SUN , Eric DEUTSCH
IPC分类号： G01N33/50 , G06T7/00 , G16H30/40 , G16H50/20
摘要： The present invention proposes a radiomics-based biomarker for detecting the presence and the density of tumor infiltrating CD8 T-cells in a solid tumor without having to use any biopsy of said tumor. The invention also proposes to use this information to assess the immune phenotype of said solid tumor. In a particular embodiment, the invention proposes to prognose the survival and/or the treatment efficiency of cancer patients treated with immunotherapy such as anti-PD-1/PD-L1 monotherapy.

82. 发明申请

US20200255912A1 TET2 as a Diagnostic and Pronostic Marker in Hematopoietic Neoplasms 审中-公开
公开(公告)号：US20200255912A1
公开(公告)日：2020-08-13
申请号：US16843507
申请日：2020-04-08
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , INSTITUT GUSTAVE-ROUSSY , Assistance Publique - Hopitaux de Paris , Centre Henri Becquerel , Universite Paris Descartes , Universite Pierre et Marie Curie , Universite Paris - SUD
发明人： Franck VIGUIE , Olivier BERNARD , Michaela FONTENAY , Christian BASTARD , Francois DELHOMMEAU , William VAINCHENKER
IPC分类号： C12Q1/6886 , G01N33/574 , A61K31/7068
摘要： The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.

83. 发明申请

US20200239961A1 PROGNOSTIC MARKER FOR MYELOPROLIFERATIVE NEOPLASMS 审中-公开
公开(公告)号：US20200239961A1
公开(公告)日：2020-07-30
申请号：US15739454
申请日：2016-06-24
申请人： Institut Gustave-Roussy
发明人： CHRISTINE BELLANNE-CHANTELOT , Isabelle PLO , William VAINCHENKER , Cécile SAINT-MARTIN , Antonio DI STEFANO , Joseph SALIBA
IPC分类号： C12Q1/6886 , G01N33/574
摘要： The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that predisposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF) secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis a secondary MDS or an AML. It also discloses a treating method for delaying MPN worsening, said treating method involving the inhibition of the ATG2B and GSKIP duplicated genes.

84. 发明申请

US20200239414A1 PROCESS FOR THE PREPARATION OF FREEZE-DRIED 2-[(3-AMINOPROPYL)AMINO]ETHANETHIOL FORMULATION 审中-公开
公开(公告)号：US20200239414A1
公开(公告)日：2020-07-30
申请号：US16465505
申请日：2017-11-29
申请人： CLEVEXEL PHARMA , INSTITUT GUSTAVE ROUSSY
发明人： Xiuping WANG-ZHANG , Perrine PIVETTE , Karine GONZALEZ , Eric DEUTSCH , Céline CLEMENSON
IPC分类号： C07C323/25 , A61P17/02 , A61K9/06 , A61K9/19
摘要： A process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol including the following steps: a) the reaction of a solution of amifostine with a strong acid, to obtain a solution of 2-[(3-aminopropyl)amino]ethanethiol, and b) the freeze-drying of the solution of 2-[(3-aminopropyl)amino]ethanethiol, with or without addition of excipients.

85. 发明申请

US20200181714A1 NOX2 as a Biomarker of Radiotherapy Efficiency in Cancer Patients 审中-公开
公开(公告)号：US20200181714A1
公开(公告)日：2020-06-11
申请号：US16333409
申请日：2017-09-19
申请人： Institut Gustave-Roussy
发明人： Jean-Luc PERFETTINI , Eric DEUTSCH , Awatef ALLOUCH
IPC分类号： C12Q1/6886 , C07K14/80
摘要： Although tumor-associated macrophages have been extensively studied in the control of response to radiotherapy, the molecular mechanisms involved in the ionizing radiation-mediated activation of macrophages remain elusive. Here the present inventors show that ionizing radiation induces the expression of interferon-regulatory factor 5 (IRF5) promoting thus macrophage activation toward a pro-inflammatory phenotype. They reveal that the activation of the Ataxia telangiectasia mutated (ATM) kinase is required for ionizing radiation-elicited macrophage activation, but also for macrophage reprogramming after treatments with γ-interferon, lipopolysaccharide or chemotherapeutic agent (such as cis-platin), underscoring the fact that the kinase ATM plays a central role during macrophage phenotypic switching toward a proinflammatory phenotype. They further demonstrate that NADPH oxidase 2 (NOX2)-dependent ROS production is upstream to ATM activation and is essential during this process. They also report that hypoxic conditions and the inhibition of any component of this signaling pathway (NOX2, ROS and ATM) impairs pro-inflammatory activation of macrophages and predicts a poor tumor response to preoperative radiotherapy in locally advanced rectal cancer. Altogether, these results identify a novel signaling pathway involved in macrophage activation that may enhance effectiveness of radiotherapy through the re-programming of tumor infiltrating macrophages.

86. 发明授权

US10493046B2 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation 有权
公开(公告)号：US10493046B2
公开(公告)日：2019-12-03
申请号：US15744345
申请日：2016-07-15
申请人： INSTITUT PASTEUR , UNIVERSITE PARIS DESCARTES , CENTRE HOSPITALIER SAINTE ANNE PARIS , INSTITUT GUSTAVE-ROUSSY
发明人： Fabrice Bruno Chretien , Raphael Gaillard , Pierre Rocheteau , Olivier Mir
IPC分类号： A61K33/00 , A61K31/138 , A61K38/00 , A61K31/685 , A61K31/495 , A61P21/00 , A61K31/496 , A61K45/06 , C12N5/077 , G01N33/50
CPC分类号： A61K31/138 , A61K31/495 , A61K31/496 , A61K45/06 , A61P21/00 , C12N5/0659 , G01N33/5061 , C12N2501/999
摘要： The present invention relates to the field of muscle regeneration, and more particularly to the replenishment of the in vivo muscle stem cells pool. It more specifically relates to a 5-hydroxytryptamine B1 receptor-stimulating agent, and to a composition comprising said agent, for use as i) a promoter of satellite cells self-renewal and/or differentiation, and/or ii) an agent preventing and/or inhibiting the satellite cells pool exhaustion. The invention further encompasses therapeutic and screening methods.

87. 发明授权

US10364430B2 Identification of a JAK2 mutation in polycythemia vera 有权
公开(公告)号：US10364430B2
公开(公告)日：2019-07-30
申请号：US14164880
申请日：2014-01-27
申请人： Institut Gustave-Roussy , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE SCIENTIFIQUE MEDICALE (INSERM) , ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS , UNIVERSITE DE VERSAILLES—ST QUENTIN EN YVELINES , UNIVERSITE PARIS-SUD
发明人： William Vainchenker , Valerie Ugo , Chloe James , Jean-Pierre Le Couedic , Nicole Casadevall
IPC分类号： C12N9/12 , C12N15/113 , C12Q1/6813 , C12Q1/6883 , G01N33/574
摘要： The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

88. 发明授权

US10125157B2 Derivatives of oxazaphosphorines that are pre-activated, use and method of preparation 有权
公开(公告)号：US10125157B2
公开(公告)日：2018-11-13
申请号：US15222316
申请日：2016-07-28
申请人： INSTITUT GUSTAVE ROUSSY
发明人： Angelo Paci , Thierry Martens , Michael Rivard , Patrick Couvreur , Didier Desmaele , Joachim Caron
IPC分类号： A01N57/36 , A61K31/66 , C07F9/6584 , C07K16/30 , A61K47/68
摘要： The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer.

89. 发明授权

US09974852B2 Mutated non-primate lentiviral Env proteins and their use as drugs 有权
公开(公告)号：US09974852B2
公开(公告)日：2018-05-22
申请号：US14896505
申请日：2014-06-06
申请人： VIROXIS S.A.S. , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT GUSTAVE ROUSSY , UNIVERSITE PARIS-SUD XI
发明人： Thierry Heidmann
IPC分类号： A61K48/00 , A61K39/00 , C12N15/00 , C12N15/63 , A61K39/21 , A61K39/12 , C07K14/005
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/53 , A61K2039/552 , A61K2039/572 , C07K14/005 , C12N2740/15022 , C12N2740/15034
摘要： A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral Env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral Env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

90. 发明申请

US20180125876A1 Methods and Pharmaceutical Composition for Modulation Polarization and Activation of Macrophages 审中-公开
公开(公告)号：US20180125876A1
公开(公告)日：2018-05-10
申请号：US15574868
申请日：2016-05-20
申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) , Université Paris sud , Institut Gustave Roussy , Institut Pasteur
发明人： Jean-Luc Perfettini , Audrey Paoletti , Marie-Lise Gougeon , Guido Kroemer , Mauro Piacentini
IPC分类号： A61K31/7072 , A61K31/7084 , A61K31/7076 , A61K31/7034 , A61K38/17 , A61K48/00 , A61P35/00 , A61P31/00 , A61P37/00 , A61P29/00
CPC分类号： A61K31/7072 , A61K31/7034 , A61K31/7076 , A61K31/7084 , A61K38/177 , A61K48/00 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/00 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/473 , Y02A50/478
摘要： The present invention relates to methods and pharmaceutical composition for modulation polarization and activation of macrophages. In particular, the present invention relates to methods for modulating macrophage M1/M2 polarization in a subject in need thereof comprising administering to the subject a therapeutically effective amount of P2Y2 receptor agonists or antagonists.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式